Navigation Links
ETHEX Corporation Voluntarily Recalls Three Lots of Dextroamphetamine Sulfate 5mg Tablets Due to the Potential for Oversized Tablets
Date:10/15/2008

Lot Number 77946, 81141 and 81142 NDC #58177-311-04

ST. LOUIS, Oct. 15 /PRNewswire/ -- ETHEX Corporation announced today that it has voluntarily recalled three specific lots (77946, 81141 and 81142) of Dextroamphetamine Sulfate 5 mg tablets, as a precaution, due to the possible presence of oversized tablets. Oversized tablets may contain as much as about twice the labeled amount of the active ingredient. The recalled lots were distributed by ETHEX Corporation under an "ETHEX" label between January 2007 and May 2008. The 5 mg product is an orange round tablet debossed with "ETHEX" and "311" on one side.

If someone were to take a higher than expected dose of Dextroamphetamine Sulfate, then the risk of adverse effects known to be associated with the drug such as tachycardia, hypertension, tremors, decreased appetite, headache, insomnia, dizziness, blurred vision, stomach upset, and dry mouth may be increased.

No report of any oversized Dextroamphetamine Sulfate tablets has been received by ETHEX from any wholesaler, retailer, consumer or caregiver, and ETHEX has not received any report of unexpected side effects or injury related to this product.

ETHEX Corporation is conducting this precautionary, voluntary recall because it found a small number of oversized tablets in lots which had not yet been distributed. These oversized tablets were removed before the lots were distributed.

Please be aware that there are multiple companies in the United States producing and marketing generic versions of Dextroamphetamine Sulfate 5 mg tablets and consumers and their caregivers are encouraged to check their prescriptions to determine the source of their tablets.

Any customer inquiries related to this action should be addressed to ETHEX Customer Service at 1-800-321-1705, or fax to ETHEX Customer Service at 314-646-3751 or sent via email to: customer-service@ethex.com with representatives
'/>"/>

SOURCE ETHEX Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. ETHEX Corporation Voluntarily Recalls a Single Lot of Morphine Sulfate 60 mg Extended Release Tablets Due to the Potential for Oversized Tablets
2. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
3. Brooke Franchise Corporation Announces Selected July Results
4. MedThink Communications Retained by NanoBio Corporation
5. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
6. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
7. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
8. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
9. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
10. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
11. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...ELHI, India, Dec. 5 He...zation today launched a global partnership to subs...ccurate and affordable alternatives. , , Th...h Asian Conference on Alternatives to Mercury in H...tions and the Indian NGO Toxics Link. , , "...
(Date:12/4/2008)... CEO marks 10th anniversary of drive to eliminate ...lionth albendazole tablet and grant to The Carter ... In a meeting today with ...nter, Jimmy Carter, as well as global health thoug...(LSE/NYSE: GSK ) announced that it has made a $2...
(Date:12/4/2008)...UKEE, Dec. 4 Aurora Health Care is...amin D supplements. Aurora,s Care Management,Clin...o educate all Aurora,caregivers about the benefit...owing evidence that higher Vitamin D levels may im...steoporosis, certain muscle conditions and,season...
(Date:12/4/2008)...RBOR, Mich., Dec. 4 BAPTIST HEALTH...., and the state,s largest health system, has,exp... Thomson Reuters -- a,solution that enabled the s...,interventions and save more than $1 million. , ...tle Rock campus show that,CareFocus prompts appro...
Breaking Medicine News(10 mins):Health News:Health Care Without Harm, WHO Announce Partnership for Global Reduction of Mercury-Based Medical Devices 2Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 2Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 3Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 4Health News:Aurora Health Care Urges All Wisconsin Residents to Take Vitamin D 2Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 2Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 3
...ssor of animal science and microbiology and molecu...te University found that a new cell// line has the...s is good news because it would result in the prod...s which is cheaper and produced in a shorter perio...
..., differences in the treatment given to male and f...ms persist, a new study has found//. In all, the ...nefit from hospitals' quality-improvement measures... the drugs, tests, and counseling about smoking, d...
...ns have succumbed to chikun gunya at Kandamanur vi... members of each family have been affected by the .../ Demanding that the government take immediate st..., vice chairperson of Mayuladumparai panchayat uni...
...g the tissue abnormalities, or lesions, that typic...men infected with multiple genotypes// of the huma...ccording to a study published in the July issue of...evention. Although doctors have known that the ce...
Other Medicine News:Health News:New Cell Lines Cuts Down the Cost and Time in the Production of Flu Vaccine 2Health News:Heart Attack Care Continues To Be Biased In Favor Of Men 2Health News:Heart Attack Care Continues To Be Biased In Favor Of Men 3Health News:Higher Risk for Cervical Cancer Seen Among Women Infected with Multiple HPV Types 2Health News:Higher Risk for Cervical Cancer Seen Among Women Infected with Multiple HPV Types 3
(Date:12/4/2008)... PARK, Calif., Dec. 4 Long-term da...expected decrease in Mitral Vale Area (MVA),after...tral regurgitation (MR),is not associated with cl...,with two years of follow-up, none of the patien...surgery for mitral stenosis. At 12 months no,impo...
(Date:12/3/2008)...igna front-line data demonstrating potential in ne...e of leukemia to be featured in two oral sessions ...benefits for chronically transfused patients by si...y organs , , - New long-term data from majo...rt on optimal post-surgery treatment strategy, Fem...
(Date:12/3/2008)...GEVILLE, Pa., Dec. 3 Wye...WYE ), announced today that it has submitted a,ma...opean Medicines Agency,(EMEA) for approval to mar...njugate vaccine (PCV13) for infants and young chil...vention of pneumococcal disease (PD) caused by the...
(Date:12/2/2008)...GO, Dec. 3 Researchers ...the circuitry in the area of the brain,responsibl...nts suffering from,stress-related psychiatric dis...day at the annual meeting of the Radiological Soci...ts with major depression and other stress-related ...
Breaking Medicine Technology:Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 2Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 3Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 2Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 3Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 4Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 5Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO 26 Investor Conference 2725 1Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO 26 Investor Conference 2725 2Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO 26 Investor Conference 2725 3Rochester Medical Announces First Quarter 2008 Earnings Conference Call February 4 2008 10053 1Rochester Medical Announces First Quarter 2008 Earnings Conference Call February 4 2008 10053 2Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 1Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 2Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 3Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2724 4Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 1Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 2Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 3Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 4Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 5Venter Institute Scientists Create First Synthetic Bacterial Genome 2723 6
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
Medicine Products: